Hemostatic System in Chronic Viral Hepatitis

REVIEW
Natalia V. Borisova, Yulia A. Popova, Snezhana S. Sleptsova, Vera N. Yadrikhinskaya, Iraida F. Bilyukina

 
International Journal of Biomedicine. 2018;8(2):102-107.   
DOI: 10.21103/Article8(2)_RA2
Originally published June 15, 2018  

Abstract: 

Hemostasis is balanced by pro- and anticoagulant and pro- and antifibrinolytic factors, most of these being synthesized by the liver. Advanced liver disease is associated with perturbations in the level of these factors due to secretory deficiencies. Thrombocytopenia, reduced levels of factor II-VII-X, and anti-fibrinolytic factors are all features of CHC infection, suggesting hypocoagulability. However, higher concentrations of VWF and factor VIII, as well as lower concentrations of anticoagulant factors including protein C and S, have also been reported in CHC infections, suggesting hypercoagulability.  Thus, the hemostatic balance in the patient with liver disease is relatively unstable as evidenced by the occurrence of both bleeding and thrombotic complications in a significant proportion of patients with chronic viral hepatitis.
In patients with chronic liver disease (CLD), in whom extremely complex alterations of hemostasis occur, one cannot rely on levels of individual coagulation factors, or on simplified tests of hemostasis such as the PT or APTT to predict the hemostatic status. To determine the hemostatic status in these patients, more complex tests and a more comprehensive overview of the hemostatic changes are required. In connection with the latest studies, a revision of the methods for correction of hemostatic system disorders in patients with acute and chronic liver diseases becomes urgent.

Keywords: 
hemostasis • chronic viral hepatitis • liver diseases • thrombocytopenia • thrombosis • bleeding • coagulopathy
References: 
  1. Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol. 2006;60(2):144-51. PubMed
  2. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116(6):878-85. doi: 10.1182/blood-2010-02-261891. PubMed
  3. Mammen EF. Coagulation defects in liver disease. Med Clin North America 1994;78:545-54. PubMed
  4.  Rak K. Thrombosis promoting changes in chronic liver diseases. Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(3):333-9. PubMed
  5. Roberts HR, Cederbaum AI. The liver and blood coagulation: physiology and pathology. Gastroenterology. 1972;63(2):297-320. PubMed
  6. Lisman T, Leebeek FWG, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol. 2002;37(2):280-287. PubMed
  7. Witters P, Freson K, Verslype C, Peerlinck K, Hoylaerts M, Nevens F, et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther. 2008;27(11):1017-29. doi: 10.1111/j.1365-2036.2008.03674.x. PubMed
  8. Bakker CM, Knot EA, Stibbe J, Wilson JH. Disseminated intravascular coagulation in liver cirrhosis. J Hepatol. 1992;15(3):330-5. PubMed
  9. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44(1):53-61. PubMed
  10. Leebeek FWG, Kluft C, Knot EAR, de Maat MPM, Wilson JHP. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology. 1991;101(5):1382-90. PubMed
  11. Bulygin VG, Dudarev VA, Bulygin GV. Structural metabolic parameters of liver tissue and indicators haemostasis in children at chronic hepatitis B. Siberian Medical Review.2013;(5):38-43.
  12. Witkop ML, Peerlinck K, Luxon BA. Medical co-morbidities of patients with hemophilia: pain, obesity and hepatitis C.  Haemophilia. 2016;22 Suppl 5:47–53. doi: 10.1111/hae.12996. PubMed
  13. Soria J, Soria C, Ryckewaert JJ, Samama M, Thomson JM, Poller L. Study of acquired dysfibrinogenaemia in liver  disease. Thromb Res. 1980;19(1-2):29-41. PubMed
  14. Geng Y, Yang J, Huang W, Harrison TJ, Zhou Y, Wen Z, et al. Virus host protein interaction network analysis reveals that the HEV ORF3 protein may interrupt the blood coagulation process. PLoS One. 2013;8(2):e56320. doi: 10.1371/journal.pone.0056320. PubMed
  15. Ratra R, Kar-Roy A, Lal SK. ORF3 protein of hepatitis E virus interacts with the Bbeta chain of fibrinogen resulting in decreased fibrinogen secretion from HuH-7 cells. J Gen Virol. 2009;90(Pt 6):1359-70. doi: 10.1099/vir.0.009274-0. PubMed
  16. Shao Z, Zhao Y, Feng L, Feng G, Zhang J, Zhang J. Association between Plasma Fibrinogen Levels and Mortality in Acute-on-Chronic Hepatitis B Liver Failure. Dis Markers. 2015;2015:468596. doi: 10.1155/2015/468596. PubMed
  17. Kim SY, Kim JE, Kim HK, Kim I, Yoon SS, Park S. Higher prognostic value of soluble fibrin complexes than D-dimer and fibrin degradation product for disseminated intravascular coagulation in patients with liver cirrhosis. Blood Coagul Fibrinolysis. 2013;24(2):150-6. doi: 10.1097/MBC.0b013e32835aef6b. PubMed
  18. Yao J, Lv G. Effect of pre-analytical variables on coagulation tests in hepatitis B patients. Blood Coagul Fibrinolysis, 2014;25(7):761–4. doi: 10.1097/MBC.0000000000000140. PubMed
  19. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M,  et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005;41(3):553-8. PubMed
  20. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000;84(5);747-51. PubMed
  21. Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost. 2011;9(9):1713-23. doi: 10.1111/j.1538-7836.2011.04429.x. PubMed
  22. Poujol‐Robert A, Boelle PY, Poupon R, Robert A. Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C. Hepatology. 2004;39(4):1174–5. PubMed
  23. Martinelli A, Knapp S, Anstee Q, Worku M, Tommasi A, Zucoloto S, et al. Effect of a thrombin receptor (protease‐activated receptor 1, PAR‐1) gene polymorphism in chronic hepatitis C liver fibrosis. J Gastroenterol Hepatol. 2008; 23(9):1403–9. PubMed
  24. Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, Hadziyannis SJ. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut. 2003;52(3):404–9. PubMed
  25. Fiorucci S, Antonelli E, Distrutti E, Severino B, Fiorentina R, Baldoni M, et al. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology. 2004;39(2):365–75. PubMed
  26. Gaca MD, Zhou X, Benyon RC. Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase‐activated receptors. J Hepatol. 2002;36(3):362–9. PubMed
  27. Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253-60.e1-4. doi: 10.1053/j.gastro.2012.07.018. PubMed
  28. Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. Br J Haematol. 2009;147(1):77-82. doi: 10.1111/j.1365-2141.2009.07833.x. PubMed
  29. Bosch J, Thabut D, Bendtsen F, D’Amico G, Albillos A, González Abraldes J, et al.;  European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double‐blind trial. Gastroenterology. 2004;127(4):1123–30. PubMed
  30. Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, et al.; International Study Group on rFVIIa in UGI Hemorrhage. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology. 2008;47(5):1604-14. doi: 10.1002/hep.22216. PubMed
  31.  Lodge JP, Jonas S, Jones RM, Olausson M, Mir‐Pallardo J, Soefelt S, et al.; rFVIIa OLT Study Group. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl. 2005;11(8):973–9. PubMed
  32. Planinsic RM, van der Meer J, Testa G, Grande L, Candela A, Porte RJ,  et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl. 2005;11(8):895–900. PubMed
  33. Widén A, Rolando N, Manousou P, Rolles K, Davidson B, Sharma D, Tuddenham E, Burroughs AK.Anticoagulation after liver transplantation: a retrospective audit and case-control study.Blood Coagul Fibrinolysis. 2009;20(8):615-8. doi: 10.1097/MBC.0b013e32832c87c8. PubMed
  34. Dhar A, Tschotazis E, Brown R. Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year. J Hepatol. 2015;62:s268–s269. Google Scholar
  35. Barclay SM, Jeffres MN, Nguyen K, Nguyen T. Evaluation of pharmacologic prophylaxis for venous thromboembolism in patients with chronic liver disease. Pharmacotherapy. 2013; 33(4):375-82. doi: 10.1002/phar.1218. PubMed
  36. Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int. 2014; 34(1):26-32. doi: 10.1111/liv.12211. PubMed
  37. Smith CB, Hurdle AC, Kemp LO, Sands C, Twilla JD. Evaluation of venous thromboembolism prophylaxis in patients with chronic liver disease. J Hosp Med. 2013;8(10):569-73. doi: 10.1002/jhm.2086. PubMed
  38. Zecchini R, Ferrari A, Bernabucci V, Lei B, Vukotic R, De Maria N, Schepis F. Anticoagulant therapy is safe and effective in preventing portal vein thrombosis in advanced cirrhotic patients: a prospective randomized controlled study. J Hepatol. 2010; 52: S460. Google Scholar
  39. Choe WH, Cho YU, Chae JD, Kim SH. Pseudothrombocytopenia or platelet clumping as a possible cause of low platelet count in patients with viral infection : a case series from single institution focusing on hepatitis A virus infection. Int J Lab Hematol. 2013;35(1):70-6. doi: 10.1111/j.1751-553X.2012.01466.x. PubMed
  40. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A. 2012;109(32):E2165-72. doi: 10.1073/pnas.1209182109. PubMed
  41. Alkozai EM, Porte RJ, Adelmeijer J, Zanetto A, Simioni P, Senzolo M, et al. No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. Thromb Res. 2015;135(2):292-7. doi: 10.1016/j.thromres.2014.11.016. PubMed
  42. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006; 44(2):440-5. PubMed
  43. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100(10):3457–69. PubMed
  44. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al.; TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227-36. PubMed
  45. Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, et al.; ELEVATE Study Group. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716-24. doi: 10.1056/NEJMoa1110709. PubMed
  46. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology. 2003;38(1):230-7. PubMed
  47. Leebeek FW, Rijken DC. The Fibrinolytic Status in Liver Diseases. Semin Thromb Hemost. 2015;41(5):474-80. doi: 10.1055/s-0035-1550437. PubMed
  48. Saray A, Mesihović R, Vukobrat-Bijedić Z, Gornjaković S, Vanis N, Mehmedović A, et al. Impact of sustained virus elimination on natural anticoagulant activity in patients with chronic viral hepatitis C. Bosn J Basic Med Sci. 2013; 13(2):84-8. PubMed
  49. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39(4):1147–71. PubMed
  50. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358(9286):958–65. PubMed
  51. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–82. PubMed
  52. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al.; PEGASYS International Study Group. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–55. PubMed
  53. Aspinall RJ, Pockros PJ.The management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther. 2004;20(9):917-29. PubMed
  54. Rribavirin.  OFFERING INFORMATION ON HIV/AIDS  TREATMENT, PREVENTION, AND RESEARCH. Available from: https://aidsinfo.nih.gov/drugs/28/ribavirin/138/professional#S5.8
  55. Iannacone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med. 2005;11(11):1167–9. PubMed
  56. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24(11):1980–7. PubMed
  57. Aiolfi R, Sitia G. Chronic hepatitis B: role of anti-platelet therapy in inflammation control. Cell Mol Immunol. 2015;12(3):264–8. doi:10.1038/2014.124. PubMed
  58. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion. 2005;45(9):1413-1425. PubMed
  59. Youssef WI, Salazar F, Dasarathy S, Beddow T, Mullen KD. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol. 2003;98(6):1391-1394. PubMed
  60.  O’Shaughnessy DF, Atterbury C, Bolton MP, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126(1):11-28. PubMed
  61. Tripodi A, Chantarangkul V, Primignani M, Clerici M, Dell'era A, Aghemo A, Mannucci PM. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. Intern Emerg Med. 2012; 7(2):139-44. doi: 10.1007/s11739-011-0528-4. PubMed

Download Article
Received May 9, 2018.
Accepted May 28, 2018.
©2018 International Medical Research and Development Corporation.